CDXS Stock Forecast: Codexis, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Codexis, Inc. is $5. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 40 of 100 as at 18 Nov 2026 — in the lower half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Codexis, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Growth (99): Sales and profits are climbing, and climbing faster than before.
Momentum (16): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
CDXS stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on CDXS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Nov 2026 | Stephens & Co. | Reiterates | Overweight | $5.00 |
| 17 Aug 2026 | Piper Sandler | Maintains | Overweight | $9.00 → $8.00 |
| 22 Nov 2024 | Cantor Fitzgerald | Reiterates | Overweight | $11 |
| 15 Nov 2024 | Cantor Fitzgerald | Reiterates | Overweight | $11 |
| 4 Nov 2024 | Benchmark | Reiterates | Hold | — |
| 20 Sept 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 29 Aug 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 19 Aug 2024 | Benchmark | Downgrade | Hold | — |
| 9 Aug 2024 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 30 May 2024 | Cantor Fitzgerald | Initiates | Overweight | — |
| 3 May 2024 | Benchmark | Reiterates | Buy | — |
| 29 Feb 2024 | Benchmark | Upgrade | Buy | — |
| 7 Nov 2023 | Benchmark | Downgrade | Hold | — |
| 6 Nov 2023 | Piper Sandler | Maintains | Overweight | — |
| 1 Sept 2023 | Benchmark | Reiterates | Buy | — |
| 14 Aug 2023 | Stifel | Maintains | Buy | — |
| 21 July 2023 | Stephens & Co. | Reiterates | Overweight | — |
| 9 May 2023 | Benchmark | Maintains | Buy | — |
| 9 May 2023 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 17 Apr 2023 | Piper Sandler | Maintains | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for CDXS.
This page is one stock. Monday covers all of them.
CDXS appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
CDXS vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 19 Nov 2026, Codexis, Inc. returned −35.8% against +9.2% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
CDXS analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 1.3×
- Price / book
- 2.3×
- EV / EBITDA
- —
Cheaper than 60% of US stocks
Cheaper than 40% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 76.5%
- Operating margin
- −14.4%
- Net margin
- —
Higher than 88% of US stocks
Higher than 24% of US stocks
- Return on equity
- −42.9%
- Return on assets
- −5.9%
- Dividend yield
- —
Higher than 24% of US stocks
Higher than 31% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Codexis, Inc. has a market value of $117.3M and an enterprise value of $116.9M.
Revenue in the twelve months to 30 June 2026: $77.7M. The latest quarter shrank 2.7% year on year.
Net income over the same four quarters: −$30.7M, a −39.6% net margin.
Diluted earnings per share, trailing twelve months: −$0.34.
Free cash flow in the twelve months to 30 June 2026: −$12.2M.
Codexis, Inc. employs 146 people — $532K of revenue per employee.
Data provided by Twelve Data
CDXS and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at CDXS’s peer groups, ranked by the model: materials stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Codexis, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about CDXS
What is the CDXS stock price forecast for 2026-2027?
The median 12-month analyst price target for Codexis, Inc. is $5, with estimates ranging from $2 to $11. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is CDXS stock a buy right now?
Of the 8 analysts covering Codexis, Inc., 6 rate it a Buy, 2 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Codexis, Inc. 40 out of 100 across roughly 4,300 US stocks as at 18 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank CDXS?
As at 18 Nov 2026, Codexis, Inc. ranks 40 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Growth (99 of 100).
Will CDXS stock go up?
No one can know that. What the data says: the median 12-month target from 8 analysts is $5, and Ticker Nerd's factor model ranks Codexis, Inc. 40 out of 100 as at 18 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the CDXS stock forecast for 2030?
No analyst covering Codexis, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CDXS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2 to $11 over the next 12 months.
How has CDXS stock performed over the past year?
Codexis, Inc. returned -35.8% over the 12 months to 19 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Codexis, Inc. do?
Codexis Inc. is a biotechnology company focused on enzyme engineering and biocatalysis. Codexis develops and commercializes proprietary protein engineering technologies that create tailored enzymes for pharmaceutical manufacturing, RNA synthesis, molecular biology, diagnostics, and other life sciences applications.
About Codexis, Inc.
Codexis Inc. is a biotechnology company focused on enzyme engineering and biocatalysis. Codexis develops and commercializes proprietary protein engineering technologies that create tailored enzymes for pharmaceutical manufacturing, RNA synthesis, molecular biology, diagnostics, and other life sciences applications. Its portfolio includes enzyme-based solutions, screening kits, and process development support designed to improve efficiency in complex manufacturing workflows. The company serves customers across the pharmaceutical, industrial, food, agricultural, and specialty chemicals markets, where engineered enzymes can help enable more precise and scalable production processes. Codexis also works on next-generation biotherapeutic and oligonucleotide manufacturing platforms, reflecting its role as a specialized provider of tools and technologies for modern drug development and advanced biological manufacturing. Headquartered in Redwood City, California, Codexis Inc. operates as a platform-driven company within the broader life sciences and synthetic biology market.
CEO Dr. Alison Moore Ph.D. · 146 employees · United States · https://www.codexis.com